Related Experiment Video
Updated: Jun 24, 2026

Alternative Therapy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Moving Cupping Along Meridians
Published on: September 27, 2024
Progression of chronic obstructive pulmonary disease: impact of inflammation, comorbidities and therapeutic
1University Hospital Birmingham NHS Foundation Trust, Birmingham, UK. r.a.stockley@bham.ac.uk
Background And Aim:
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality, and through under-diagnosis, is often inappropriately treated. This multicomponent disease involves both airway and systemic inflammation at all stages and may influence the progression of disease and the pathophysiology of comorbidities. This review examines evidence linking inflammation, disease progression and comorbidities in COPD, and the potential role of anti-inflammatory therapies.
Methods:
Systematic searches of Medline and Cochrane Reviews databases from 1976 to March 2008 using the terms: chronic obstructive pulmonary disease, disease progression, inflammation, inflammatory, comorbid condition, comorbidity, treatment, therapy, bronchodilator, inhaled corticosteroid.
Findings:
Increased levels of interleukin-8, tumour necrosis factor-alpha and systemic C-reactive protein correlate with worse disease severity, exacerbation rates and lung function decline. Increased systemic C-reactive protein is also associated with poorer health status and comorbidities (e.g. cardiovascular disease, cancer and skeletal muscle dysfunction). The pivotal role of inflammation in the pathogenesis of COPD and its comorbidities suggests anti-inflammatory therapies will be important in the overall management of COPD. Long-term studies indicate that combination therapies consisting of a long-acting beta-agonist plus an inhaled corticosteroid in one inhaler have the potential to modify disease progression through positive effects on lung function, exacerbations, symptoms and health status. The TOwards a Revolution in COPD Health (TORCH) study is the first to demonstrate that a COPD pharmacotherapy (combination salmeterol plus fluticasone propionate) significantly decreased the rate of lung function decline versus placebo.
Conclusion:
Better understanding of the specific inflammatory mechanisms underlying COPD disease progression and associated comorbidities will likely lead to more effective management of the disease.
Related Concept Videos
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
